Developer docs
API playgroundTry for free, no card

Search company profiles

Arvelle Therapeutics

Full company profile

uuid0002e66

Namestring
Arvelle Therapeutics
Legal namestring
Arvelle Therapeutics
Websiteurl
arvelletx.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Arvelle Therapeutics was a clinical-stage biopharmaceutical company headquartered in Basel, Switzerland, founded in 2019 by Mark Altmeyer, a biopharma executive with over 35 years of industry experience. The company was focused on developing innovative therapeutics for central nervous system (CNS) disorders, operating within the pharmaceutical R&D value chain from preclinical development through clinical milestones.

Arvelle was built as an asset-focused vehicle around a proprietary CNS pipeline, financed primarily through venture capital rather than commercial revenue. The company secured approximately $221.8 million across two financing rounds — a ~$179.1 million Series A in February 2019 led by EQT Life Sciences, and a ~$42.7 million follow-on in May 2020 — drawing a syndicate that included BPV Capital Management, Andera Partners, H.I.G. BioHealth Partners, KB Investment, F-Prime, and Novaquest Capital Management. With 51–100 employees and a Switzerland-based operating footprint, Arvelle's go-to-market strategy was oriented toward clinical advancement and value-inflection rather than commercial sales.

Within approximately two years of founding, Arvelle was acquired by Angelini Pharma, a strategic pharmaceutical operator, for $1 billion. This transaction delivered a full exit to investors and absorbed Arvelle's pipeline into Angelini's broader CNS-adjacent franchise. Post-acquisition, founder Mark Altmeyer departed to chair ReproNovo, and Arvelle ceased to operate as an independent entity.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersZug, Switzerland
HQ citystring
Zug
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
biopharmaceutical development, CNS therapeutics, clinical-stage pharmaceuticals, neurology drug development, central nervous system therapies
Industry2 codes
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
CNS Therapeutics
No data
Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Arvelle Therapeutics was a clinical-stage biopharmaceutical company focused on developing innovative CNS therapeutics. Founded in 2019 in Basel, Switzerland, the company built a development pipeline targeting central nervous system disorders and was acquired by Angelini Pharma for $1 billion within approximately two years of its founding, having secured $200 million in private financing prior to the acquisition.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Arvelle Therapeutics was a clinical-stage biopharmaceutical company focused on fertility and women's health. The company operated in the pharmaceutical development space, with no software or technology products identified in the available source data.

Product and service1 record
1CNS Therapeutics Development Pipeline
CategoryCNS Therapeutics / Biopharmaceuticals
Description

Clinical-stage development pipeline targeting central nervous system disorders; intended for eventual commercialization by pharmaceutical acquirers and partners serving neurology patients.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Market position
Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Arvelle Therapeutics

CNS Therapeuticsarvelletx.com

What Arvelle Therapeutics does

Arvelle Therapeutics was a clinical-stage biopharmaceutical company headquartered in Basel, Switzerland, founded in 2019 by Mark Altmeyer, a biopharma executive with over 35 years of industry experience. The company was focused on developing innovative therapeutics for central nervous system (CNS) disorders, operating within the pharmaceutical R&D value chain from preclinical development through clinical milestones.

Arvelle was built as an asset-focused vehicle around a proprietary CNS pipeline, financed primarily through venture capital rather than commercial revenue. The company secured approximately $221.8 million across two financing rounds — a ~$179.1 million Series A in February 2019 led by EQT Life Sciences, and a ~$42.7 million follow-on in May 2020 — drawing a syndicate that included BPV Capital Management, Andera Partners, H.I.G. BioHealth Partners, KB Investment, F-Prime, and Novaquest Capital Management. With 51–100 employees and a Switzerland-based operating footprint, Arvelle's go-to-market strategy was oriented toward clinical advancement and value-inflection rather than commercial sales.

Within approximately two years of founding, Arvelle was acquired by Angelini Pharma, a strategic pharmaceutical operator, for $1 billion. This transaction delivered a full exit to investors and absorbed Arvelle's pipeline into Angelini's broader CNS-adjacent franchise. Post-acquisition, founder Mark Altmeyer departed to chair ReproNovo, and Arvelle ceased to operate as an independent entity.

Arvelle Therapeutics firmographics

Firmographics
Name
Arvelle Therapeutics
Legal name
Arvelle Therapeutics
Website
https://arvelletx.com
Company type
Private
Founded year
2021
Operating status
Acquired
Headcount range
51–100 employees
Ownership category
akta.pro rank

Arvelle Therapeutics industry classification

Industry
Product category
CNS Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Biopharmaceutical development
  • CNS therapeutics
  • Clinical-stage pharmaceuticals
  • Neurology drug development
  • Central nervous system therapies

Where Arvelle Therapeutics is headquartered

Location

Headquarters

HQ city
Zug
HQ country
Switzerland
HQ region
Europe

Markets served

Arvelle Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Arvelle Therapeutics product offering

Product offering

Core offering

Arvelle Therapeutics was a clinical-stage biopharmaceutical company focused on developing innovative CNS therapeutics. Founded in 2019 in Basel, Switzerland, the company built a development pipeline targeting central nervous system disorders and was acquired by Angelini Pharma for $1 billion within approximately two years of its founding, having secured $200 million in private financing prior to the acquisition.

Product overview

Arvelle Therapeutics was a clinical-stage biopharmaceutical company focused on fertility and women's health. The company operated in the pharmaceutical development space, with no software or technology products identified in the available source data.

Differentiator

Problem solved

Functional benefit

Products and services

  • CNS Therapeutics Development Pipeline Clinical-stage development pipeline targeting central nervous system disorders; intended for eventual commercialization by pharmaceutical acquirers and partners serving neurology patients.

Companies that use Arvelle Therapeutics

Customer profile

Ideal customer profiles1 record

Arvelle Therapeutics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Arvelle Therapeutics partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Arvelle Therapeutics competitors and assessment

Company assessment

Market position

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Arvelle Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Arvelle Therapeutics leadership team

Management profile

Number of profiles

Arvelle Therapeutics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Arvelle Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Arvelle Therapeutics

What does Arvelle Therapeutics do?

Arvelle Therapeutics was a clinical-stage biopharmaceutical company focused on developing innovative CNS therapeutics. Founded in 2019 in Basel, Switzerland, the company built a development pipeline targeting central nervous system disorders and was acquired by Angelini Pharma for $1 billion within approximately two years of its founding, having secured $200 million in private financing prior to the acquisition.

Is Arvelle Therapeutics a public or private company?

Arvelle Therapeutics is a private company. It is classified as corporate owned and is currently acquired.

When was Arvelle Therapeutics founded?

Arvelle Therapeutics was founded in 2021. It employs 51 to 100 people.

Where is Arvelle Therapeutics based?

Arvelle Therapeutics is headquartered in Zug, Switzerland, in the Europe region.

Does Arvelle Therapeutics have an API?

No public API is recorded for Arvelle Therapeutics.

What industry is Arvelle Therapeutics in?

Arvelle Therapeutics's product category is CNS Therapeutics. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireLong-Term Safety and Tolerability of XCOPRI® (cenobamate tablets) CV Published in EpilepsiaSK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co., Ltd., announced that long-term safety and tolerability data for its anti-seizure medication cenobamate (XCOPRI) were published in the journal Epilepsia, with the open-label extension study enrolling 149 patients who completed the prior 12-week C013 study. The study demonstrated a 57% retention rate (85/149) at a median treatment duration of 6.25 years, with a 59% probability of continuing treatment for 6 years and 54% of patients able to discontinue at least one concomitant anti-seizure medication. SK Biopharmaceuticals has licensed cenobamate to Arvelle Therapeutics (now under Angelini Pharma) for Europe and to Ono Pharmaceutical for Japan.PR NewswireONTOZRY® (Cenobamat) erhält EU-Zulassung für die Behandlung von medikamentenresistenten fokalen epileptischen Anfällen bei ErwachsenenThe European Commission granted market authorization for ONTOZRY® (Cenobamate) as adjunctive therapy for focal seizures in adults with drug-resistant epilepsy, valid across all EU member states, Iceland, Norway, and Liechtenstein. The approval was based on three clinical trials enrolling over 1,900 patients, including a pivotal multicenter double-blind randomized placebo-controlled study published in The Lancet Neurology. Angelini Pharma, which recently acquired biopharmaceutical company Arvelle Therapeutics, announced the approval.GlobeNewswireSio Gene Therapies Announces Receipt of $11.6 Million from Closing of the Sale of Arvelle TherapeuticsSio Gene Therapies received $11.6 million from the sale of Arvelle Therapeutics to Angelini Pharma. Additional payments, including about $4.8 million by mid-2021 upon EMA approval of cenobamate, are expected. The company also highlighted its gene therapy pipeline for neurodegenerative diseases.GlobeNewswireONTOZRY™ (cenobamate) receives positive CHMP opinion for the adjunctive treatment of uncontrolled focal onset seizures in adults*The European Medicines Agency's CHMP recommended approval of cenobamate for adjunctive treatment of uncontrolled focal seizures in adults. The decision is expected within 67 days, and Angelini Pharma will acquire Arvelle Therapeutics to commercialize it in Europe. Angelini plans to launch the drug by Q2 2021.PR NewswireCenobamate Receives Positive CHMP Opinion for Adjunctive Treatment of Focal-Onset (Partial-Onset) SeizuresSK Biopharmaceuticals announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of cenobamate for adjunctive treatment of focal-onset seizures in adult epilepsy patients in the European Union. The European Commission is expected to issue its final decision within approximately 67 days. SK Biopharmaceuticals entered into a licensing agreement with Arvelle Therapeutics in 2019 for European commercialization, and Angelini Pharma—which is acquiring Arvelle—plans to launch the drug under the brand name ONTOZRY following final EC approval.PR NewswireAngelini Pharma acquires Arvelle Therapeutics to create a leading European innovator in Central Nervous System (CNS) and Mental Health Disorder treatmentsAngelini Pharma has acquired Arvelle Therapeutics in an all-cash transaction valued at up to $960 million, with $610 million paid upfront and an additional $350 million contingent on cenobamate reaching certain revenue targets. The acquisition gives Angelini Pharma exclusive rights to commercialize cenobamate, an FDA-approved anti-seizure medication, across the European Union, Switzerland, and the United Kingdom, pending EMA approval expected in 2021. SK Biopharmaceuticals sold its 12 percent stake in Arvelle Therapeutics as part of this deal, while the transaction is described by Angelini executives as the most important investment in the Group's history.FinSMEsAngelini Pharma Acquires Arvelle Therapeutics, for Up To $960MAngelini Pharma acquired Arvelle Therapeutics in an all-cash deal valued at up to $960M, with $610M paid immediately and $350M contingent on revenue targets. The deal gives Angelini exclusive rights to commercialize cenobamate in Europe, with EMA approval expected in 2021.PR NewswireAngelini Pharma adquiere Arvelle TherapeuticsAngelini Pharma, a company belonging to the Italian Angelini Group, has announced the acquisition of Swiss biopharmaceutical company Arvelle Therapeutics for a total value of $960 million, with $610 million payable upon regulatory approval and the remaining $350 million contingent on revenue milestones. The deal grants Angelini exclusive rights to commercialize cenobamate, a treatment for focal-onset seizures, across the European Union and other European Economic Area countries, pending EMA approval expected in 2021. SK Biopharmaceuticals, which held a 12% stake in Arvelle, has agreed to sell its position to Angelini as part of the transaction.PR NewswireAngelini Pharma acquiert Arvelle Therapeutics pour créer un innovateur européen de premier plan dans le domaine du système nerveux central (SNC) et des traitements contre les troubles mentauxAngelini Pharma, a company belonging to the Italian private group Angelini, has entered into a definitive merger agreement to acquire Swiss biopharmaceutical company Arvelle Therapeutics in an all-cash transaction valued at up to $960 million, with $610 million payable upfront upon regulatory approval and an additional $350 million contingent on cenobamate achieving certain revenue targets. Following the acquisition, Angelini will obtain exclusive rights to commercialize cenobamate, an innovative anti-epileptic drug, across the European Union, European Economic Area, Switzerland, and the United Kingdom, pending EMA approval expected in 2021. SK Biopharmaceuticals, which held a 12% stake in Arvelle, agreed to sell its position to Angelini as part of the transaction, with SK remaining eligible to receive payments under its 2019 licensing agreement with Arvelle.